Nevertheless, targeted PD-1/PD-L1 therapy yields unsatisfactory outcomes in osteosarcoma (52), possibly attributed to the distinct PD-1/PD-L1 regulation in the tumor, commonly known as a “cold tumor” (53). This evidence concerns the gene PDCD1 and neoplasm.